<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02203253</url>
  </required_header>
  <id_info>
    <org_study_id>CLOG1302</org_study_id>
    <nct_id>NCT02203253</nct_id>
  </id_info>
  <brief_title>Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting</brief_title>
  <official_title>Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting From Highly Emetogenic Chemotherapy: a Randomized, Multicenter, Double-blind, Placebo-controlled Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Hospital of Liaoning Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third People's hospital Liaoyang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Petrochemical General Hospital of Liaoyang city</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anshan Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Medical University, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was aimed to evaluate efficacy and tolerability of thalidomide in improving
      prevention of chemotherapy-induced delayed nausea and vomiting in chemotherapy-naive patients
      after highly emetogenic chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, multi-center, double-blind, placebo-controlled clinical
      trial, aimed to evaluate efficacy and tolerability of thalidomide in improving prevention of
      chemotherapy-induced delayed nausea and vomiting (CINV) in chemotherapy-naive patients after
      highly emetogenic chemotherapy(HEC) (cisplatin-based regimen or cyclophosphamide combination
      with doxorubicin/epirubicin). A total of 820 patients are planned to be enrolled into the
      study. Patients treating with highly emetogenic chemotherapy will be randomized into two
      groups, and be treated with Thalidomide+ Palonosetron+ Dexamethasone or Placebo +
      Palonosetron+ Dexamethasone, respectively. The primary end point is complete response rate
      (CRR) for delayed CINV, and the secondary end points include the safety and quality of life
      (QOL).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete response rate (CRR) for delayed CINV</measure>
    <time_frame>120 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">642</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Thalidomide Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thalidomide 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (for Thalidomide) tablet 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>100 mg by mouth twice a day on days 1-5 after chemotherapy, cycle 1</description>
    <arm_group_label>Thalidomide Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for thalidomide</intervention_name>
    <description>Placebo tablet manufactured to mimic Thalidomide 25 mg tablet 100 mg by mouth twice a day on days 1-5 after chemotherapy , cycle 1</description>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>Placebo tablet for thalidomide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron and Dexamethasone</intervention_name>
    <description>Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.</description>
    <arm_group_label>Thalidomide Group</arm_group_label>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18y ≤Age≤70y

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

          -  Histologically confirmed solid neoplasm

          -  No prior chemotherapy

          -  Laboratory test must meet the following criteria: hemoglobin (HGB) ≥90g/L, neutrophil
             count ≥1.5×109/L, platelet count ≥85×109/L, creatinine clearance rate (CCr) ≥60ml/min,
             total bilirubin (TBil) ≤1.5 upper normal limitation (UNL), alanine aminotransferase
             (ALT) and aspartate aminotransferase (AST) ≤2.5 UNL (For patients with liver
             metastasis, the AST/ALT must be ≤5.0 UNL), blood glucose ≤11.1 mmol/L

          -  Life expectancy of at least 12 weeks

          -  Signed informed consent

          -  For women with child bearing potential, a negative serum or urine pregnancy test
             result should be obtained before enrollment

          -  Cancer patients scheduled to receive HEC regimen. The HEC regimen was defined as
             chemotherapy containing a 50 mg/m2 or higher dose of cisplatin, or cyclophosphamide
             combination with doxorubicin/epirubicin

        Exclusion Criteria:

          -  Diabetic patients

          -  Pregnant or lactated women

          -  Patient with history of thrombosis

          -  Concomitant radiotherapy

          -  Known hypersensitivity to thalidomide, palonosetron, or dexamethasone.

          -  Concurrent administration of any other drug which affect antiemetic effect evaluation
             such as proton pump inhibitor, H2 blocker, amifostine, sedative drugs

          -  CHOP regiment or taxanes-based regiment

          -  Existing emesis within 24 hours before chemotherapy administration

          -  Symptomatic brain metastasis or suspected clinical brain metastasis

          -  Serious uncontrolled systemic illness or medical condition: congestive heart failure,
             unstable angina, history of documented myocardial infarction within 6 months,
             uncontrolled hypertension and high risk uncontrollable arrhythmias; Obvious
             neurological or mental abnormalities including mental disorder, epileptic dementia,
             which affect compliance; Uncontrolled acute infections; Uncontrolled peptic ulcer or
             other contraindication for corticosteroid therapy.

          -  Inability to take or absorb oral medicine

          -  Concurrent administration of any other investigational drug, or have been enrolled in
             other clinical trial with investigational drug treatment within the 30 days of start
             of study treatment

          -  Unsuitable for the study or other chemotherapy determined by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yunpeng Liu, MD., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Medical University, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anshan Tumor Hospital</name>
      <address>
        <city>Anshan</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Liaoning Medical University</name>
      <address>
        <city>Jinzhou</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liaoyang Central Hospital</name>
      <address>
        <city>Liaoyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petrochemical General Hospital of Liaoyang city</name>
      <address>
        <city>Liaoyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Third People's hospital Liaoyang</name>
      <address>
        <city>Liaoyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Shenyang Military Region</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liaoning Tumor Hospital &amp; Institute</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2014</study_first_submitted>
  <study_first_submitted_qc>July 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2014</study_first_posted>
  <last_update_submitted>August 23, 2016</last_update_submitted>
  <last_update_submitted_qc>August 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Medical University, China</investigator_affiliation>
    <investigator_full_name>Yunpeng Liu</investigator_full_name>
    <investigator_title>M.D.,PhD</investigator_title>
  </responsible_party>
  <keyword>solid tumor</keyword>
  <keyword>chemotherapy-induced delayed nausea and vomiting</keyword>
  <keyword>thalidomide</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

